Compounds for the treatment of auricular fibrillation
US8012973B2 · kind B2 · utility
0Cited by
5References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 10, 2006 |
| Grant date | Sep 6, 2011 |
| Priority date | — |
| Expiry date | Sep 28, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Adenosine A2A receptor antagonists are useful for the preparation of medicaments against atrial fibrillation in mammals, including humans. It has been found that the adenosine A2A receptor is present in human atrial cardiomyocytes and participates in the pathological mechanisms underlying atrial fibrillation. An advantage of using A2A antagonists over other agents known in the art is that the A2A antagonists specifically target patients with atrial fibrillation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.